Join        Login             Stock Quote

The Metrics of Growth in China Biopharma

 May 17, 2008 05:13 PM

The healthcare market in China is certainly growing, and so are the companies that serve the market, though the parameters used to measure that growth may differ for each biopharma. For public companies, the quarterly earning statement delivers a significant analysis of a biopharma's measure of success, and last week, China biopharmas continued to roll out Q1 reports that were remarkable for their uniformly positive news. But for private companies, the metrics have to be different. In ChinaBio® Today last week, we published examples of both types of stories.

GenePharma, a young and growing private company that provides research tools to the hot siRNA market, was the subject of a profile that included an exclusive interview with its founder and CEO, Dr. Peter Zhang (see story). GenePharma has recently made two announcements that testify to its ambitious plans: the company is opening a new manufacturing a facility in BioBay Park near Suzhou, and it acquired a patent license from Alnylam (NSDQ: alny). The patent license allows GenePharma to sell its siRNA products worldwide. Combining low prices with excellent service – and an explosive market for siRNA products – GenePharma is well-positioned for growth. The company is also a textbook example of the sea turtle phenomenon, the convergence of recent historical and economic trends that has made China a preferred location for siting biopharma enterprises.

No fewer than four China-based, American-listed biopharmas disclosed their Q1 financial reports during the last week. Each announced revenue growth of at least 39%, and two were able to say their sales had more than doubled.

China Sky One (OTCBB:cski.ob), with a remarkable 140% jump in revenue ($12.4 million) and a 170% climb in net income ($3.9 million), wins the Most Improved award for companies reporting this week (see story). To continue its growth, China Sky One completed two acquisitions in the beginning of Q2 that will continue its growth. One acquisition, Heilongjiang Tianlong Pharma, is a competitor of China Sky One in the niche of externally-applied (patches, sprays, ointments) drugs, and the other addition, Heilongjiang Haina Pharma, has a Good Supply Practice license that allows distribution of drugs. Meanwhile, China Sky One continues to expand its in-vitro diagnostic test offerings, and the company is applying for listing on the American Stock Exchange. Presently, China Sky One is listed on the OTC Bulletin Board.

Next Page >>12
iOnTheMarket Premium


Comments Closed

rss feed

Latest Stories

article imageGermany Is On The Rebound - Time To Buy?

Based on this year's 17% spike in the Stoxx Europe 600 Index, it seems investors have found a home in read on...

article imageIs Drought Risk In The American West An Economic Threat?

The historic and ongoing drought in California is getting harder to ignore in terms of its potential impact read on...

article imageFunds Behaving Badly

Discipline is still the key to read on...

article imageGenuine Parts Co. (GPC): This Company's Raised Dividends For 59 Years

There are 253 million cars and trucks driving along U.S. roads. And the average age of those automobiles is read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.